Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Tumor Targeting with Apatinib-loaded Nanoparticles and Sonodynamic Combined Therapy

Author(s): Xiao Han, Caifu Zhou, Xiaoling Luo*, Hongbing Pang, Chuangye Han, Libo Tang, Ziye Yang, Yingdan Nong and Chunmiao Lu

Volume 24, Issue 5, 2024

Published on: 06 July, 2023

Page: [648 - 666] Pages: 19

DOI: 10.2174/1566524023666230613140341

Price: $65

Abstract

Introduction: This study implies the enhancement of apatinib killing effect in 4T1 tumor cells through constructing drug-loaded nanoparticles apatinib/Ce6@ZIF- 8@Membranes (aCZM) to enhance tumor therapeutic targeting and reduce toxic side following sonodynamic therapy (SDT).

Methods: apatinib/Ce6@ZIF-8 (aCZ) were synthesized by in situ encapsulation, and aCZM were constructed by encapsulating the nanoparticles with extracted breast cancer 4T1 cell membranes. aCZM were characterized and tested for the stability by electron microscopy, and the membrane proteins on the nanoparticles’ surface were assessed using SDS-PAGE gel electrophoresis. The cell viability of 4T1 cells following treatment with aCZM was tested using cell counting kit-8 (CCK-8). The uptake of nanoparticles was detected by laser confocal microscopy and flow cytometry, and the SDT-mediated production of reactive oxygen species (ROS) was verified by singlet oxygen sensor green (SOSG), electron spin resonance (ESR), and DCFH-DA fluorescent probes. The CCK-8 assay and flow cytometry using Calcein/PI were used to assess the antitumoral effect of aCZM nanoparticles under SDT. The biosafety of aCZM was further verified in vitro and in vivo using the hemolysis assay, routine blood test and H&E staining of vital organs in Balb/c mice.

Results: aCZM with an average particle size of about 210.26 nm were successfully synthesized. The results of the SDS-PAGE gel electrophoresis experiment showed that aCZM have a band similar to that of pure cell membrane proteins. The CCK-8 assay demonstrated the absence of effects on cell viability at a low concentration range, and the relative cell survival rate reached more than 95%. Laser confocal microscopy and flow cytometry analysis showed that aCZM treated group has the strongest fluorescence and the highest cellular uptake of nanoparticles. SOSG, ESR, and DCFH-DA fluorescent probes all indicated that the aCZM + SDT treated group has the highest ROS production. The CCK-8 assay also showed that when the ultrasound intensity was fixed at 0.5 W/cm2, the relative cell survival rates in the medium concentration group (10 μg/ml) (5.54 ± 1.26%) and the high concentration group (20 μg/ml) (2.14 ± 1.63%) were significantly lower than those in the low concentration group (5 μg/ml) (53.40 ± 4.25%). Moreover, there was a concentration and intensity dependence associated with the cellkilling effect. The mortality rate of the aCZM in the ultrasound group (44.95 ± 3.03%) was significantly higher than that of the non-ultrasound (17.00 ± 2.26%) group and aCZ + SDT group (24.85 ± 3.08%) (P<0.0001). The live and dead cells’ staining (Calcein/PI) also supported this result. Finally, in vitro hemolysis test at 4 and 24 hours showed that the hemolysis rate of the highest concentration group was less than 1%. The blood routine, biochemistry, and H&E staining results of major organs in Balb/c mice undergoing nano-treatments showed no obvious functional abnormalities and tissue damage in 30 days.

Conclusion: In this study, a multifunctional bionic drug delivery nanoparticles (aCZM) system with good biosafety and compatibility in response to acoustic dynamics was successfully constructed and characterized. This system enhanced apatinib killing effect on tumor cells and reduced toxic side effects under SDT.

« Previous Next »
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Rossi L, Mazzara C, Pagani O. Diagnosis and treatment of breast cancer in young women. Curr Treat Options Oncol 2019; 20(12): 86.
[http://dx.doi.org/10.1007/s11864-019-0685-7] [PMID: 31776799]
[3]
George LA, Sullivan SK, Giermasz A, et al. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med 2017; 377(23): 2215-27.
[http://dx.doi.org/10.1056/NEJMoa1708538] [PMID: 29211678]
[4]
Li W, Yang J, Luo L, et al. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat Commun 2019; 10(1): 3349.
[http://dx.doi.org/10.1038/s41467-019-11269-8] [PMID: 31350406]
[5]
Xie C, Duffy AG, Mabry-Hrones D, et al. Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer. Hepatology 2019; 69(5): 2048-60.
[http://dx.doi.org/10.1002/hep.30482] [PMID: 30578687]
[6]
Peng QX, Han YW, Zhang YL, et al. Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma. Oncotarget 2017; 8(32): 52813-22.
[http://dx.doi.org/10.18632/oncotarget.17264] [PMID: 28881773]
[7]
Liu K, Ren T, Huang Y, et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis 2017; 8(8): e3015.
[http://dx.doi.org/10.1038/cddis.2017.422] [PMID: 28837148]
[8]
Fathi Maroufi N, Rashidi MR, Vahedian V, Akbarzadeh M, Fattahi A, Nouri M. Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance. Life Sci 2020; 241117106.
[http://dx.doi.org/10.1016/j.lfs.2019.117106] [PMID: 31786193]
[9]
Lin S, Zang M. Effects of apatinib mesylate monotherapy on the incidence of adverse reactions and immune function in patients with breast cancer after radical mastectomy. Evid Based Complement Alternat Med 2022; 2022: 1-6.
[http://dx.doi.org/10.1155/2022/4022282] [PMID: 35990841]
[10]
Han W, Shi L, Xie B, et al. Supramolecular engineering of molecular inhibitors in an adaptive cytotoxic nanoparticle for synergistic cancer therapy. ACS Appl Mater Interfaces 2020; 12(1): 1707-20.
[http://dx.doi.org/10.1021/acsami.9b20178] [PMID: 31816241]
[16]
Zhang Q, Li L. Photodynamic combinational therapy in cancer treatment. J BUON 2018; 23(3): 561-7. [J]
[PMID: 30003719]
[17]
Son S, Kim JH, Wang X, et al. Multifunctional sonosensitizers in sonodynamic cancer therapy. Chem Soc Rev 2020; 49(11): 3244-61.
[http://dx.doi.org/10.1039/C9CS00648F] [PMID: 32337527]
[18]
Zhao H, Zhao B, Li L, et al. Biomimetic decoy inhibits tumor growth and lung metastasis by reversing the drawbacks of sonodynamic therapy. Adv Healthc Mater 2020; 9(1): 1901335.
[http://dx.doi.org/10.1002/adhm.201901335] [PMID: 31762228]
[19]
Guo H, Wang J. Impact of contrast ultrasound diagnosis for patients with liver cancer. Medicine 2019; 98(19): e15445.
[http://dx.doi.org/10.1097/MD.0000000000015445] [PMID: 31083175]
[20]
You DG, Deepagan VG, Um W, et al. ROS-generating TiO2 nanoparticles for non-invasive sonodynamic therapy of cancer. Sci Rep 2016; 6(1): 23200.
[http://dx.doi.org/10.1038/srep23200] [PMID: 26996446]
[21]
Zhu H, He Y, Huang S, et al. Chlorin e6-loaded sonosensitive magnetic nanoliposomes conjugated with the magnetic field for enhancing anti-tumor effect of sonodynamic therapy. Pharm Dev Technol 2020; 25(10): 1249-59.
[http://dx.doi.org/10.1080/10837450.2020.1810274] [PMID: 32811263]
[22]
Meng L, Cheng Y, Tong X, et al. Tumor oxygenation and hypoxia inducible factor-1 functional inhibition via a reactive oxygen species responsive nanoplatform for enhancing radiation therapy and abscopal effects. ACS Nano 2018; 12(8): 8308-22.
[http://dx.doi.org/10.1021/acsnano.8b03590] [PMID: 30102510]
[23]
Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000; 6(2): 572-7.
[PMID: 10690541]
[24]
Kosharskyy B, Solban N, Chang SK, Rizvi I, Chang Y, Hasan T. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res 2006; 66(22): 10953-8.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-1793] [PMID: 17108133]
[25]
Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C 2019; 98: 1252-76.
[http://dx.doi.org/10.1016/j.msec.2019.01.066] [PMID: 30813007]
[26]
Kang H, Rho S, Stiles WR, et al. Size dependent EPR effect of polymeric nanoparticles on tumor targeting. Adv Healthc Mater 2020; 9(1): 1901223.
[http://dx.doi.org/10.1002/adhm.201901223] [PMID: 31794153]
[27]
Sun CY, Qin C, Wang XL, et al. Zeolitic imidazolate framework-8 as efficient pH-sensitive drug delivery vehicle. Dalton Trans 2012; 41(23): 6906-9.
[http://dx.doi.org/10.1039/c2dt30357d] [PMID: 22580798]
[28]
An J, Hu YG, Li C, et al. A pH/Ultrasound dual-response biomimetic nanoplatform for nitric oxide gas-sonodynamic combined therapy and repeated ultrasound for relieving hypoxia. Biomaterials 2020; 230119636.
[http://dx.doi.org/10.1016/j.biomaterials.2019.119636] [PMID: 31785776]
[29]
Gao L, Chen Q, Gong T, Liu J, Li C. Recent advancement of imidazolate framework (ZIF-8) based nanoformulations for synergistic tumor therapy. Nanoscale 2019; 11(44): 21030-45.
[http://dx.doi.org/10.1039/C9NR06558J] [PMID: 31674617]
[30]
Hou Z, Zhu K, Yang X, et al. Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: A phase II clinical trial. Ann Transl Med 2020; 8(17): 1047.
[http://dx.doi.org/10.21037/atm-20-2990] [PMID: 33145266]
[31]
Qu F, Wang P, Zhang K, et al. Manipulation of mitophagy by “All-in-One” nanosensitizer augments sonodynamic glioma therapy. Autophagy 2020; 16(8): 1413-35.
[http://dx.doi.org/10.1080/15548627.2019.1687210] [PMID: 31674265]
[32]
Wang C, Chen P, Qiao Y, et al. pH responsive superporogen combined with PDT based on poly Ce6 ionic liquid grafted on SiO 2 for combating MRSA biofilm infection. Theranostics 2020; 10(11): 4795-808.
[http://dx.doi.org/10.7150/thno.42922] [PMID: 32308750]
[33]
Chen Z, Zhao P, Luo Z, et al. Cancer cell membrane–biomimetic nanoparticles for homologous-targeting dual modal imaging and photothermal therapy. ACS Nano 2016; 10(11): 10049-57.
[http://dx.doi.org/10.1021/acsnano.6b04695] [PMID: 27934074]
[34]
Karakeçili A, Topuz B, Korpayev S, Erdek M. Metal-organic frameworks for on-demand pH controlled delivery of vancomycin from chitosan scaffolds. Mater Sci Eng C 2019; 105110098.
[http://dx.doi.org/10.1016/j.msec.2019.110098] [PMID: 31546383]
[35]
Min H, Wang J, Qi Y, et al. Biomimetic metal–organic framework nanoparticles for cooperative combination of antiangiogenesis and photodynamic therapy for enhanced efficacy. Adv Mater 2019; 31(15): 1808200.
[http://dx.doi.org/10.1002/adma.201808200] [PMID: 30773718]
[36]
Liao Y, Luo H, He Z, et al. A combination of UTMD-mediated HIF-1 α shRNA transfection and TAE in the treatment of hepatic cancer. BioMed Res Int 2019; 2019: 1-8.
[http://dx.doi.org/10.1155/2019/1937460] [PMID: 30911540]
[37]
Chen ZY, Wang YX, Zhao YZ, et al. Apoptosis induction by ultrasound and microbubble mediated drug delivery and gene therapy. Curr Mol Med 2014; 14(6): 723-36.
[http://dx.doi.org/10.2174/1566524014666140804165245] [PMID: 25088226]
[38]
Zhang Y, Zhang X, Yang H, et al. Advanced biotechnology assisted precise sonodynamic therapy. Chem Soc Rev 2021; 50(20): 11227-48.
[http://dx.doi.org/10.1039/D1CS00403D] [PMID: 34661214]
[39]
Trendowski M. The promise of sonodynamic therapy. Cancer Metastasis Rev 2014; 33(1): 143-60.
[http://dx.doi.org/10.1007/s10555-013-9461-5] [PMID: 24346159]
[40]
Rengeng L, Qianyu Z, Yuehong L, Zhongzhong P, Libo L. Sonodynamic therapy, a treatment developing from photodynamic therapy. Photodiagn Photodyn Ther 2017; 19: 159-66.
[http://dx.doi.org/10.1016/j.pdpdt.2017.06.003] [PMID: 28606724]
[41]
Costley D, Mc Ewan C, Fowley C, et al. Treating cancer with sonodynamic therapy: A review. Int J Hyperthermia 2015; 31(2): 107-17.
[http://dx.doi.org/10.3109/02656736.2014.992484] [PMID: 25582025]
[42]
Dai S, Xu C, Tian Y, Cheng W, Li B. In vitro stimulation of calcium overload and apoptosis by sonodynamic therapy combined with hematoporphyrin monomethyl ether in C6 glioma cells. Oncol Lett 2014; 8(4): 1675-81.
[http://dx.doi.org/10.3892/ol.2014.2419] [PMID: 25202390]
[43]
Sun X, Xu H, Shen J, et al. Real-time detection of intracellular reactive oxygen species and mitochondrial membrane potential in THP-1 macrophages during ultrasonic irradiation for optimal sonodynamic therapy. Ultrason Sonochem 2015; 22: 7-14.
[http://dx.doi.org/10.1016/j.ultsonch.2014.06.016] [PMID: 25023826]
[44]
Tachibana K, Feril LB Jr, Ikeda-Dantsuji Y. Sonodynamic therapy. Ultrasonics 2008; 48(4): 253-9.
[http://dx.doi.org/10.1016/j.ultras.2008.02.003] [PMID: 18433819]
[45]
Meng Y, Zou C, Madiyalakan R, et al. Water-soluble and biocompatible sono/photosensitizer nanoparticles for enhanced cancer therapy. Nanomedicine 2010; 5(10): 1559-69.
[http://dx.doi.org/10.2217/nnm.10.91] [PMID: 21143033]
[46]
Pan X, Bai L, Wang H, et al. Metal-organic-framework-derived carbon nanostructure augmented sonodynamic cancer therapy. Adv Mater 2018; 30(23): 1800180.
[http://dx.doi.org/10.1002/adma.201800180] [PMID: 29672956]
[47]
Liu Y, Bai L, Guo K, et al. Focused ultrasound-augmented targeting delivery of nanosonosensitizers from homogenous exosomes for enhanced sonodynamic cancer therapy. Theranostics 2019; 9(18): 5261-81.
[http://dx.doi.org/10.7150/thno.33183] [PMID: 31410214]
[48]
Wagner A, Liu Q, Rose OL, et al. Toxicity screening of two prevalent metal organic frameworks for therapeutic use in human lung epithelial cells. Int J Nanomedicine 2019; 14: 7583-91.
[http://dx.doi.org/10.2147/IJN.S215950] [PMID: 31571865]
[49]
Lin Y, Zhong Y, Chen Y, et al. Ligand-modified erythrocyte membrane-cloaked metal–organic framework nanoparticles for targeted antitumor therapy. Mol Pharm 2020; 17(9): 3328-41.
[http://dx.doi.org/10.1021/acs.molpharmaceut.0c00421] [PMID: 32804508]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy